Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

Official Title: “Efficacy and Safety of Ciprofloxacin Extended-Release 1000 mg Once-Daily Versus Ciprofloxacin Immediate-Release 500 mg Twice-Daily Given 7-14 Days in Patients With Complicated Urinary Tract Infections: Prospective, Randomized, Double-Blind Trial.”

To assess and compare the efficacy and safety of ciprofloxacin extended-release (CIPRO XR) tablet 1000 mg PO once-daily (OD) versus ciprofloxacin immediate-release (CIPRO IR) tablet 500 mg PO twice-daily (BID) for 7-14 days in patients with complicated and/or nosocomial urinary tract infections (cUTI).

Intervention(s) in this Clinical Trial

• Drug: Cipro XR (Ciprofloxacin, BAYQ3939)
  • Ciprofloxacin XR 1000 mg orally once a day
• Drug: Cipro IR (Ciprofloxacin, BAYQ3939)
  • Ciprofloxacin IR 500 mg orally twice a day

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: Arm 1
• Experimental: Arm 2

Primary Measures

• Bacteriological response 5 to 9 days after the last dose of study medication (TOC visit).
  • Time Frame: 5-9 days
    Safety Issue?: No

Secondary Measures

• Bacteriological outcome during treatment
  • Time Frame: 7-14 days
    Safety Issue?: No
• Bacteriological outcome at follow-up
  • Time Frame: 28-42 days
    Safety Issue?: No
• Clinical outcome during treatment
  • Time Frame: 7-14 days
    Safety Issue?: No
• Clinical outcome at the test-of-cure visit
  • Time Frame: 5-9 days
    Safety Issue?: No
• Clinical outcome at follow-up
  • Time Frame: 28-42 days
    Safety Issue?: No
• Adverse event collection
  • Time Frame: 28-42 days
    Safety Issue?: No

Inclusion Criteria:

• The primary diagnosis in this clinical trial was cUTI in men or non-pregnant women over 18 years of age. Other main inclusion criteria:
• One or more clinical symptoms and signs of a lower UTI: fever (> 38°C, orally), chills, frequency of micturition, dysuria, urge sensation.
• One or more of the following underlying conditions suggestive of cUTI:
• Indwelling urinary catheter.
• 100 mL of residual urine after voiding.
• Neurogenic bladder.
• Obstructive uropathy due to lithiasis, tumor or fibrosis.
• Acute urinary retention in men.

Exclusion Criteria:

• Diagnosis of pyelonephritis supported by clinical signs/symptoms of fever (>38°C orally), chills and flank pain (all 3 signs/symptoms must be present).
• Have a history of allergy to quinolones
• Are unable to take oral medication
• Have an intractable infection requiring > 14 days of therapy
• Have a requirement for concomitant administration of sucralfate or divalent and trivalent cations such as iron or antacids containing magnesium, aluminum or calcium
• Have prostatitis or epididymitis
• Have had a renal transplant
• Have ileal loop or vesica- urethral reflux
• Have significant liver or kidney impairment
• Have a history of tendinopathy associated with fluoroquinolones
• Are pregnant, nursing
• Have a history of convulsions or CNS disorders

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Bayer Industry

Overall Clinical Trial Officials and Contacts

Bayer Study Director Study Director Bayer  

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00668122

Study ID Number: 11454

ClinicalTrials.gov Identifier: NCT00668122

Health Authority: Italy: The Italian Medicines Agency

Click here and search for drug information provided by the FDA

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product